Changeflow GovPing Healthcare & Life Sciences Porous Particles Patent, Lucideon Limited, Apr ...
Routine Notice Added Final

Porous Particles Patent, Lucideon Limited, Apr 2026

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published patent application EP3236946A1 for porous particles by Lucideon Limited on April 15, 2026. The inventors are Philip Richard Jackson, Mark Cresswell, and Ian F. Campbell, with the application classified under pharmaceutical formulation codes A61K 9/14, A61K 9/16, A61K 9/20, and A61K 31/00. The patent designation extends across all European Patent Convention contracting states including Germany, France, the United Kingdom, Italy, Spain, and 25 others. Pharmaceutical manufacturers developing similar porous particle formulations should evaluate freedom-to-operate implications within the designated states.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.

What changed

The EPO published patent application EP3236946A1 for porous particles by Lucideon Limited, inventors Philip Richard Jackson, Mark Cresswell, and Ian F. Campbell, classified under pharmaceutical formulation codes A61K 9/14, A61K 9/16, A61K 9/20, and A61K 31/00. The patent is designated across all EPC contracting states. Pharmaceutical manufacturers developing similar porous particle formulations in the A61K space should assess freedom-to-operate implications within the designated states.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

POROUS PARTICLES

Publication EP3236946A1 Kind: A1 Apr 15, 2026

Applicants

Lucideon Limited

Inventors

JACKSON, Philip Robert, CRESSWELL, Mark, CAMPBELL, Ian F.

IPC Classifications

A61K 9/14 20060101AFI20160707BHEP A61K 9/16 20060101ALI20160707BHEP A61K 9/20 20060101ALI20160707BHEP A61K 31/00 20060101ALI20160707BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3236946A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application IP licensing Product development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!